Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/27/2020 10:29 PDT] Puma Biotechnology, Inc. (NASDAQ:PBYI), Down By 100.00% ($13.03) From $13.030 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [05/19/2020 08:07 PDT] PBYI Expected to Trade Down After Bearish Patterns Develop
• [05/08/2020 07:43 PDT] PBYI, Expected to Trade Lower After Bearish Insider Trading
• [05/01/2020 07:32 PDT] PBYI Expected to Trade Down After Bearish Patterns Develop
• [04/07/2020 08:11 PDT] PBYI, Expected to Trade Lower After Bearish Insider Trading
• [04/03/2020 12:23 PDT] Puma Biotechnology, Inc. (NASDAQ:PBYI), Down By 100.00% ($8.43) From $8.430 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions